New Study Reveals Key Factors That Influence How Quickly Prostate Cancer Becomes Resistant to Hormone Therapy

ASCO GU 2025: Continuous ADT Remains Superior to Intermittent Therapy in Metastatic Hormone-Sensitive Prostate Cancer